Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

Res Sq. 2020 Oct 8:rs.3.rs-86289. doi: 10.21203/rs.3.rs-86289/v1. Preprint.


The COVID-19 pandemic progresses unabated in many regions of the world. An effective antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication was observed in animals when the drug was administered either beginning 12 hours before or 12 hours following infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 infection in humans following high-risk exposure as well as for treatment of COVID-19 patients.

PMID:33052329 | PMC:PMC7553153 | DOI:10.21203/rs.3.rs-86289/v1